PDCD1 and cancer: The emergence of immunotherapies targeting checkpoint proteins such as PD-1, PD-L1 and CTLA-4 has revolutionized the treatment of many cancers, including melanoma and non-small cell lung cancer, where these therapies lead to a meaningful improvement in the overall survival of patients with metastatic disease [7–10].